⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for stage iii grade 3 follicular lymphoma

Every month we try and update this database with for stage iii grade 3 follicular lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's LymphomaNCT00005959
Lymphoma
filgrastim
rituximab
cyclophosphamid...
doxorubicin hyd...
prednisone
vincristine sul...
18 Years - National Cancer Institute (NCI)
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative DiseaseNCT00176475
Leukemia
Lymphoma
Multiple Myelom...
rituximab
therapeutic all...
18 Years - Rutgers, The State University of New Jersey
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's LymphomaNCT00244946
Lymphoma
therapeutic aut...
carmustine
cytarabine
etoposide
melphalan
peripheral bloo...
15 Years - 70 YearsBarbara Ann Karmanos Cancer Institute
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's LymphomaNCT00017381
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Extranodal Marg...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Stage I Adult D...
Stage I Adult D...
Stage I Grade 1...
Stage I Grade 2...
Stage I Grade 3...
Stage I Mantle ...
Stage I Margina...
Stage I Small L...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Waldenström Mac...
rituximab
cyclophosphamid...
filgrastim
yttrium Y 90 ib...
peripheral bloo...
18 Years - 70 YearsNational Cancer Institute (NCI)
Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular LymphomaNCT00020462
Lymphoma
aldesleukin
autologous tumo...
18 Years - National Cancer Institute (NCI)
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent LymphomaNCT00980395
Lymphoma
Mantle Cell Lym...
Indolent Lympho...
SLL
rituximab
bortezomib
cladribine
18 Years - University of Arizona
Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin LymphomaNCT01190449
Lymphoma
ofatumumab
18 Years - Alliance for Clinical Trials in Oncology
Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's LymphomaNCT00428142
Lymphoma
rituximab
bortezomib
cyclophosphamid...
prednisone
vincristine sul...
18 Years - 120 YearsCanadian Cancer Trials Group
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell CancersNCT00003163
Lymphoma
Multiple Myelom...
filgrastim
sargramostim
cyclophosphamid...
melphalan
autologous bone...
peripheral bloo...
radiation thera...
18 Years - National Cancer Institute (NCI)
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionNCT00118170
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory Mult...
Splenic Margina...
Stage II Multip...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Multi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Waldenström Mac...
sorafenib tosyl...
pharmacological...
18 Years - National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With LymphomaNCT00002835
Lymphoma
Bleomycin Sulfa...
Filgrastim (G-C...
Recombinant Int...
Carmustine
Cisplatin (CDDP...
Cyclophosphamid...
Cytarabine (ARA...
Etoposide (VP-1...
Idarubicin
Ifosfamide
Leucovorin Calc...
Melphalan
Methotrexate
Methylprednisol...
mitoxantrone hy...
Vincristine Sul...
Peripheral Bloo...
Radiation Thera...
15 Years - 59 YearsM.D. Anderson Cancer Center
S8809-S9800-S9911-S9704-A Study of Blood and Tissue Samples From Patients With Follicular Lymphoma Treated With Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and PrednisoneNCT00933127
Lymphoma
DNA analysis
polymerase chai...
polymorphism an...
laboratory biom...
18 Years - SWOG Cancer Research Network
Denileukin Diftitox in Treating Patients With Non-Hodgkin's LymphomaNCT00026429
Leukemia
Lymphoma
denileukin dift...
18 Years - National Cancer Institute (NCI)
Low-Dose Radiation Therapy in Treating Patients With Follicular or Marginal Zone Non-Hodgkin's LymphomaNCT00310167
Lymphoma
radiation thera...
18 Years - University College, London
Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's LymphomaNCT00004179
Lymphoma
rituximab
CHOP regimen
cyclophosphamid...
doxorubicin hyd...
prednisone
vincristine sul...
18 Years - 120 YearsEuropean Organisation for Research and Treatment of Cancer - EORTC
Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular LymphomaNCT01307605
Lymphoma
Rituximab
lenalidomide
18 Years - Swiss Group for Clinical Cancer Research
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's LymphomaNCT00003397
Lymphoma
filgrastim
rituximab
sargramostim
carmustine
cisplatin
cyclophosphamid...
dexamethasone
etoposide
gemcitabine hyd...
melphalan
paclitaxel
bone marrow abl...
peripheral bloo...
18 Years - 75 YearsUniversity of Maryland, Baltimore
Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic CancersNCT00003572
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
peripheral bloo...
mycophenolate m...
tacrolimus
allogeneic bone...
radiation thera...
18 Years - 70 YearsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid CancerNCT00248430
Graft Versus Ho...
Leukemia
Lymphoma
Multiple Myelom...
aldesleukin
therapeutic all...
melphalan
bone marrow abl...
peripheral bloo...
18 Years - 69 YearsFred Hutchinson Cancer Center
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionNCT00118170
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory Mult...
Splenic Margina...
Stage II Multip...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Multi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Waldenström Mac...
sorafenib tosyl...
pharmacological...
18 Years - National Cancer Institute (NCI)
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic SyndromeNCT00002989
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
busulfan
cyclophosphamid...
idarubicin
melphalan
radiation thera...
16 Years - 60 YearsNational Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's LymphomaNCT00002565
Lymphoma
bleomycin sulfa...
CHOP regimen
cisplatin
cyclophosphamid...
cytarabine
doxorubicin hyd...
etoposide
idarubicin
ifosfamide
mesna
methylprednisol...
mitoxantrone hy...
prednisone
vincristine sul...
15 Years - M.D. Anderson Cancer Center
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell LymphomaNCT00670358
Lymphoma
pegfilgrastim
rituximab
cyclophosphamid...
doxorubicin hyd...
lenalidomide
prednisone
vincristine sul...
polymorphism an...
laboratory biom...
18 Years - 120 YearsMayo Clinic
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin LymphomaNCT01045928
Adult Non-Hodgk...
Adult Grade III...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Cutaneous B-cel...
Extranodal Marg...
Nodal Marginal ...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage I Adult B...
Stage I Adult D...
Stage I Adult D...
Stage I Adult D...
Stage I Adult I...
Stage I Adult L...
Stage I Grade 1...
Stage I Grade 2...
Stage I Grade 3...
Stage I Mantle ...
Stage I Margina...
Stage I Small L...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Waldenstrom Mac...
lenalidomide
rituximab
polymerase chai...
nucleic acid se...
polymorphism an...
flow cytometry
laboratory biom...
18 Years - Case Comprehensive Cancer Center
Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHLNCT00732498
Lymphoma
Methylprednisol...
Etoposide
Cytarabine
Cisplatin
Rituximab
In-Zevalin
Y-Zevalin
18 Years - University of Arizona
UCN-01 in Treating Patients With Advanced CancerNCT00003289
Leukemia
Lymphoma
Unspecified Adu...
7-hydroxystauro...
18 Years - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic CancerNCT00010192
B-cell Adult Ac...
Extranodal Marg...
Nodal Marginal ...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
rituximab
aldesleukin
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI)
Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's LymphomaNCT00117975
Lymphoma
galiximab
rituximab
18 Years - Alliance for Clinical Trials in Oncology
Combination Chemotherapy in Treating Patients With Aggressive Non-Hodgkin's LymphomaNCT00005867
Lymphoma
bleomycin sulfa...
CHOP regimen
cyclophosphamid...
doxorubicin hyd...
etoposide
mitoxantrone hy...
prednisolone
vincristine sul...
18 Years - 59 YearsNational Cancer Institute (NCI)
Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic CancerNCT00296023
Chronic Myelopr...
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
anti-thymocyte ...
filgrastim
therapeutic all...
busulfan
fludarabine pho...
methotrexate
tacrolimus
nonmyeloablativ...
peripheral bloo...
18 Years - 75 YearsUniversity of California, San Francisco
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By ChemotherapyNCT00003341
Anemia
Leukemia
Lymphoma
Multiple Myelom...
epoetin alfa
quality-of-life...
18 Years - Memorial Sloan Kettering Cancer Center
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic CancerNCT00290641
Chronic Myelopr...
Leukemia
Lymphoma
Myelodysplastic...
filgrastim
graft-versus-tu...
cyclophosphamid...
cyclosporine
fludarabine pho...
mycophenolate m...
umbilical cord ...
radiation thera...
- 45 YearsMasonic Cancer Center, University of Minnesota
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's LymphomaNCT00003204
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Small...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Small ...
cyclophosphamid...
fludarabine pho...
vincristine sul...
prednisone
rituximab
laboratory biom...
18 Years - National Cancer Institute (NCI)
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic CancerNCT00782379
Leukemia
Lymphoma
Myelodysplastic...
busulfan
cyclophosphamid...
fludarabine pho...
mycophenolate m...
tacrolimus
allogeneic hema...
peripheral bloo...
18 Years - 60 YearsNorthside Hospital, Inc.
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's LymphomaNCT00006721
Lymphoma
rituximab
cyclophosphamid...
doxorubicin
prednisone
vincristine
tositumomab
18 Years - SWOG Cancer Research Network
Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's LymphomaNCT00110006
Lymphoma
rituximab
cyclophosphamid...
doxorubicin hyd...
prednisone
vincristine sul...
positron emissi...
fludeoxyglucose...
18 Years - Case Comprehensive Cancer Center
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent LymphomaNCT00980395
Lymphoma
Mantle Cell Lym...
Indolent Lympho...
SLL
rituximab
bortezomib
cladribine
18 Years - University of Arizona
GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin LymphomaNCT00896519
Lymphoma
rituximab
sargramostim
cyclophosphamid...
doxorubicin hyd...
prednisone
vincristine sul...
gene expression...
gene rearrangem...
polymerase chai...
R-CHOP regimen
laboratory biom...
18 Years - National Cancer Institute (NCI)
Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin LymphomaNCT00553501
Lymphoma
epratuzumab
rituximab
18 Years - Alliance for Clinical Trials in Oncology
Chemotherapy Plus Interferon Alfa Alone or With Radiation Therapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's LymphomaNCT00003152
Lymphoma
filgrastim
recombinant int...
cyclophosphamid...
prednisone
vincristine sul...
autologous bone...
bone marrow abl...
peripheral bloo...
radiation thera...
18 Years - 65 YearsEuropean Organisation for Research and Treatment of Cancer - EORTC
Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell LymphomaNCT00411086
Lymphoma
Rituximab
Sargramostim (G...
18 Years - M.D. Anderson Cancer Center
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell CancersNCT00003163
Lymphoma
Multiple Myelom...
filgrastim
sargramostim
cyclophosphamid...
melphalan
autologous bone...
peripheral bloo...
radiation thera...
18 Years - National Cancer Institute (NCI)
Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's LymphomaNCT00089115
Lymphoma
autologous immu...
rituximab
sargramostim
18 Years - National Cancer Institute (NCI)
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous LeukemiaNCT00275080
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Blastic Phase C...
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Secondary Acute...
Splenic Margina...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Untreated Adult...
Untreated Adult...
vorinostat
decitabine
18 Years - National Cancer Institute (NCI)
Tipifarnib in Treating Patients With Advanced Hematologic CancerNCT00005967
Chronic Myelopr...
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
tipifarnib
18 Years - National Cancer Institute (NCI)
Denileukin Diftitox in Treating Patients With Non-Hodgkin's LymphomaNCT00026429
Leukemia
Lymphoma
denileukin dift...
18 Years - National Cancer Institute (NCI)
Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's LymphomaNCT00003605
Lymphoma
rituximab
cyclophosphamid...
- Hoag Memorial Hospital Presbyterian
Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's LymphomaNCT00387959
Leukemia
Lymphoma
filgrastim
rituximab
cyclophosphamid...
cyclosporine
fludarabine pho...
mycophenolate m...
allogeneic hema...
umbilical cord ...
total-body irra...
18 Years - 70 YearsMemorial Sloan Kettering Cancer Center
UCN-01 in Treating Patients With Advanced CancerNCT00003289
Leukemia
Lymphoma
Unspecified Adu...
7-hydroxystauro...
18 Years - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's LymphomaNCT00006721
Lymphoma
rituximab
cyclophosphamid...
doxorubicin
prednisone
vincristine
tositumomab
18 Years - SWOG Cancer Research Network
High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's LymphomaNCT00003578
Lymphoma
CHOP regimen
carmustine
cyclophosphamid...
cytarabine
doxorubicin hyd...
etoposide
melphalan
prednisone
vincristine sul...
autologous bone...
peripheral bloo...
16 Years - 65 YearsNational Cancer Institute (NCI)
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or LeukemiaNCT00004084
Leukemia
Lymphoma
indium In 111 L...
yttrium Y 90 ep...
18 Years - Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's LymphomaNCT00301795
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
oblimersen sodi...
rituximab
laboratory biom...
18 Years - National Cancer Institute (NCI)
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic CancerNCT00004061
Leukemia
Lymphoma
Oral Complicati...
filgrastim
palifermin
cyclophosphamid...
etoposide
ifosfamide
peripheral bloo...
quality-of-life...
radiation thera...
18 Years - 65 YearsNational Cancer Institute (NCI)
Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous TherapyNCT00006220
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
arsenic trioxid...
tretinoin
15 Years - Washington University School of Medicine
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic CancerNCT00004061
Leukemia
Lymphoma
Oral Complicati...
filgrastim
palifermin
cyclophosphamid...
etoposide
ifosfamide
peripheral bloo...
quality-of-life...
radiation thera...
18 Years - 65 YearsNational Cancer Institute (NCI)
Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin LymphomaNCT00553501
Lymphoma
epratuzumab
rituximab
18 Years - Alliance for Clinical Trials in Oncology
Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaNCT00026351
Leukemia
Lymphoma
rituximab
pentostatin
18 Years - National Cancer Institute (NCI)
Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell LymphomaNCT00411086
Lymphoma
Rituximab
Sargramostim (G...
18 Years - M.D. Anderson Cancer Center
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's LymphomaNCT00244946
Lymphoma
therapeutic aut...
carmustine
cytarabine
etoposide
melphalan
peripheral bloo...
15 Years - 70 YearsBarbara Ann Karmanos Cancer Institute
Chlorambucil Compared With Radiation Therapy in Treating Patients With Previously Untreated Stage III or Stage IV Follicular LymphomaNCT00028691
Lymphoma
chlorambucil
radiation thera...
18 Years - National Cancer Institute (NCI)
S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's LymphomaNCT00003784
Lymphoma
CHOP regimen
cyclophosphamid...
doxorubicin hyd...
prednisone
vincristine sul...
tositumomab and...
18 Years - SWOG Cancer Research Network
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell TransplantNCT00725062
Graft Versus Ho...
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
CD4+CD25+ regul...
allogeneic hema...
18 Years - 70 YearsMasonic Cancer Center, University of Minnesota
GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin LymphomaNCT00893477
Lymphoma
rituximab
sargramostim
gene expression...
gene rearrangem...
polymerase chai...
polymorphism an...
laboratory biom...
18 Years - National Cancer Institute (NCI)
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's LymphomaNCT00003338
Lymphoma
immunoscintigra...
technetium Tc 9...
16 Years - 120 YearsGilead Sciences
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's LymphomaNCT00244946
Lymphoma
therapeutic aut...
carmustine
cytarabine
etoposide
melphalan
peripheral bloo...
15 Years - 70 YearsBarbara Ann Karmanos Cancer Institute
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell LymphomaNCT00670358
Lymphoma
pegfilgrastim
rituximab
cyclophosphamid...
doxorubicin hyd...
lenalidomide
prednisone
vincristine sul...
polymorphism an...
laboratory biom...
18 Years - 120 YearsMayo Clinic
S8809-S9800-S9911TM- Biological Markers in Patients With Follicular Lymphoma Treated on Clinical Trial SWOG-8809, SWOG-9800, or SWOG-9911NCT00896922
Lymphoma
microarray anal...
immunohistochem...
laboratory biom...
16 Years - 120 YearsSWOG Cancer Research Network
Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin LymphomaNCT00637832
Lymphoma
rituximab
cyclophosphamid...
doxorubicin hyd...
prednisolone
vincristine sul...
yttrium Y 90 ib...
18 Years - 120 YearsUniversity of Southampton
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's LymphomaNCT00017381
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Extranodal Marg...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Stage I Adult D...
Stage I Adult D...
Stage I Grade 1...
Stage I Grade 2...
Stage I Grade 3...
Stage I Mantle ...
Stage I Margina...
Stage I Small L...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Waldenström Mac...
rituximab
cyclophosphamid...
filgrastim
yttrium Y 90 ib...
peripheral bloo...
18 Years - 70 YearsNational Cancer Institute (NCI)
Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's LymphomaNCT00079261
Lymphoma
Small Intestine...
CHOP regimen
cyclophosphamid...
doxorubicin hyd...
gemcitabine hyd...
prednisone
vincristine sul...
18 Years - 70 YearsEuropean Organisation for Research and Treatment of Cancer - EORTC
Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast CancerNCT00005993
Breast Cancer
Lymphoma
aldesleukin
filgrastim
recombinant hum...
peripheral bloo...
18 Years - 65 YearsMasonic Cancer Center, University of Minnesota
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell TransplantNCT00725062
Graft Versus Ho...
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
CD4+CD25+ regul...
allogeneic hema...
18 Years - 70 YearsMasonic Cancer Center, University of Minnesota
Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's LymphomaNCT00028665
Lymphoma
filgrastim
rituximab
carmustine
cisplatin
cyclophosphamid...
etoposide
bone marrow abl...
peripheral bloo...
radiation thera...
12 Years - 65 YearsCase Comprehensive Cancer Center
Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's LymphomaNCT00017290
Lymphoma
autologous immu...
keyhole limpet ...
sargramostim
cyclophosphamid...
prednisone
vincristine sul...
18 Years - National Cancer Institute (NCI)
Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's LymphomaNCT00443976
Non-Hodgkins Ly...
Unspecified Adu...
Aurora kinase i...
18 Years - Canadian Cancer Trials Group
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's LymphomaNCT00004197
Lymphoma
keyhole limpet ...
sargramostim
tumor cell-base...
cyclophosphamid...
doxorubicin hyd...
mitoxantrone hy...
prednisone
vincristine sul...
18 Years - 120 YearsUniversity of Nebraska
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular LymphomaNCT01216683
Lymphoma
rituximab
Bendamustin
bortezomib
lenalidomide
18 Years - Eastern Cooperative Oncology Group
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and MelphalanNCT00577278
Graft Versus Ho...
Leukemia
Lymphoma
rituximab
fludarabine pho...
melphalan
sirolimus
tacrolimus
allogeneic hema...
indium In 111 i...
yttrium Y 90 ib...
laboratory biom...
18 Years - 69 YearsCity of Hope Medical Center
Combination Chemotherapy in Treating Patients With Aggressive Non-Hodgkin's LymphomaNCT00005867
Lymphoma
bleomycin sulfa...
CHOP regimen
cyclophosphamid...
doxorubicin hyd...
etoposide
mitoxantrone hy...
prednisolone
vincristine sul...
18 Years - 59 YearsNational Cancer Institute (NCI)
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: